These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 8916471)

  • 1. Estrogens--pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation--Estring.
    Johnston A
    Acta Obstet Gynecol Scand Suppl; 1996; 163():16-25. PubMed ID: 8916471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic data on estradiol in light of the estring concept. Estradiol and estring pharmacokinetics.
    Gabrielsson J; Wallenbeck I; Birgerson L
    Acta Obstet Gynecol Scand Suppl; 1996; 163():26-31; discussion 32-4. PubMed ID: 8916472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
    Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
    Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet.
    Weisberg E; Ayton R; Darling G; Farrell E; Murkies A; O'Neill S; Kirkegard Y; Fraser IS
    Climacteric; 2005 Mar; 8(1):83-92. PubMed ID: 15804736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A morphologist's approach to the vagina.
    Forsberg JG
    Acta Obstet Gynecol Scand Suppl; 1996; 163():3-10. PubMed ID: 8916469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.
    Baker VL
    Obstet Gynecol Clin North Am; 1994 Jun; 21(2):271-97. PubMed ID: 7936545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication.
    Gregersen N; Jensen PT; Giraldi AE
    Dan Med Bull; 2006 Aug; 53(3):349-53. PubMed ID: 17092454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets.
    Panay N; Maamari R
    Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and efficacy of different estrogens are not equivalent.
    Ansbacher R
    Am J Obstet Gynecol; 2001 Feb; 184(3):255-63. PubMed ID: 11228470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCPL delivery system as a model for E + P replacement therapy in post-ovariectomized adult rats mimicking a postmenopausal condition.
    Cason Z; Benghuzzi H; Tucci M; England B
    Biomed Sci Instrum; 2003; 39():529-34. PubMed ID: 12724947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following IM single dose administration in healthy postmenopausal volunteers.
    Schug BS; Donath F; Blume HH
    Int J Clin Pharmacol Ther; 2012 Feb; 50(2):100-17. PubMed ID: 22257576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Topical hormonal treatment and urogenital atrophy].
    Sitruk-Ware R; Thomas JL
    Praxis (Bern 1994); 1997 Aug; 86(33):1245-8. PubMed ID: 9381009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vulvovaginal atrophy: new and upcoming approaches.
    Simon JA
    Menopause; 2009; 16(1):5-7. PubMed ID: 19131842
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review.
    Sarkar NN
    Eur J Contracept Reprod Health Care; 2003 Dec; 8(4):217-24. PubMed ID: 15006269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estradiol vaginal inserts (Imvexxy): effective in genitourinary syndrome of menopause without increasing systemic estrogen levels.
    Paton DM
    Drugs Today (Barc); 2018 Nov; 54(11):667-677. PubMed ID: 30539166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics and pharmacology of estrogens in pre- and postmenopausal women.
    Anderson F
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():55-64. PubMed ID: 8499960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
    Bachmann G; Lobo RA; Gut R; Nachtigall L; Notelovitz M
    Obstet Gynecol; 2008 Jan; 111(1):67-76. PubMed ID: 18165394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.